Stock Ratings / Health Care / SLDB / financials

IAM (50) ATTO (47) FDMT (40) CADL (38) ⌘ Pro Terminal →

Solid Biosciences Inc. (SLDB) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$6.39 -1.39% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.36

Solid Biosciences Inc. (SLDB) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $685.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.36 (-0.44%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-12.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SLDB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY SLDB SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (26% of score)

FRED Regime × Technicals: 34% of 52W Range • RSI-14 at 42.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$6.87-19.5% Next Q

Q2 (-2Q)

Grade E$5.53+7.1% Next Q

Q3 (-1Q)

Grade E$5.92+7.9% Next Q

Current

Grade E$6.39-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SLDB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SLDB currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.81) and Max Pain ($6.71) forces dealer call-delta covering toward $12.02.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SLDB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SLDB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SLDB Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-4.5%	$0	-$157.4M	-45%
FY 2024	$4.00B	52%	-3.2%	$0	-$100.7M	-45%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SLDB)

✓Walkthrough of SLDB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SLDB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.98%▼ DESCENDING CHANNEL

2026-10-30O $6.30H $6.43L $6.02C $6.39VOL 873.1K

RES: $9.62SUP: $4.95SMA50: $7.81SMA200: $7.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SLDB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SLDB Butterfly Map → + Track SLDB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SLDB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SLDB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SLDB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SLDB)

Health Care Rank #913 of 1016 ⚔️ IAM vs SLDB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SLDB vs. IAM, ATTO, FDMT, CADL)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Solid Biosciences Inc. (SLDB) ranks #913 by composite RQD confidence (31/100, grade E) and #402 by equity capitalization ($685.2M). Within this direct 5-issuer industry benchmark cohort, SLDB leads on earnings valuation at N/A trailing P/E, while FDMT leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. IAM currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with SLDB at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SLDB ACTIVE Solid Biosciences Inc.	E	31/100	—	—	-35.0%	-1.39%	$685.2M	Benchmark Subject
IAM Iambic Therapeutics Inc.	D	50/100	—	—	—	-3.38%	$676.9M	/iam-vs-sldb →
ATTO Attovia Therapeutics Inc.	D	47/100	—	—	—	-3.35%	$697.1M	/atto-vs-sldb →
FDMT 4D Molecular Therapeutics Inc.	D-	40/100	—	—	-28.3%	-1.16%	$706.0M	/fdmt-vs-sldb →
CADL Candel Therapeutics Inc.	D-	38/100	—	—	-35.0%	-0.23%	$661.9M	/cadl-vs-sldb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001707502

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Solid Biosciences Inc. (SLDB) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $0, operating cash flow of -$156.3M, and free cash flow of -$157.4M (-56.4% YoY). On the balance sheet, SLDB closed FY2025 with $232.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	-$156.3M	-$157.4M	$232.5M	—
FY2024 (FY)	2024-12-31	$0	$0	-$100.0M	-$100.7M	$188.7M	—

3. SLDB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SLDB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Solid Biosciences Inc. (NASDAQ: SLDB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $6.39 (-1.39% 1D, market cap $685.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SLDB ranks #913 in composite RQD confidence.

How does SLDB compare to IAM and ATTO in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SLDB carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IAM (Iambic Therapeutics Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $676.9M) and ATTO (Attovia Therapeutics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $697.1M). Among the 5-stock peer group, SLDB leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SLDB?

Per SLDB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001707502), Solid Biosciences Inc. generated $0 in revenue, $0 in net income, and -$157.4M in free cash flow against $232.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SLDB trading relative to its 50-day, 200-day, and 52-week technical levels?

SLDB last traded at $6.39 (-1.39% on volume of 964,679 shares), positioning the stock -18.18% below its 50-day simple moving average ($7.81) and -16.58% below its 200-day simple moving average ($7.66). Across its 52-week range of $3.79 to $11.45, SLDB sits at the 33.9% percentile with a 14-day RSI of 42.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.59 to $7.19).

SLDB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Solid Biosciences Inc. (SLDB)?

In FY 2025 (10-K), SLDB converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: SLDB RQD Cockpit SLDB 12M Forecast SLDB Earnings & Move SLDB Dividends & DRIP SLDB Insiders & 13F SLDB Whale Options SLDB Profit Sankey SLDB News & Why